MedTrace Logo

Influence of Triflusal on Cognitive Functions in Healthy Subjects

NCT02321852 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-11-10

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of the eNOS activating agent triflusal on episodic memory and cognitive functions in healthy participants.

Conditions

  • Healthy

Interventions

DRUG

Triflusal

Once daily oral administration of 600 mg triflusal Disgren® for 7 days.

DRUG

Placebo

Once daily oral administration of placebo mannitol for 7 days

Sponsors & Collaborators

  • Prof. Dominique de Quervain, MD

    lead OTHER

Principal Investigators

  • Dominique De Quervain, MD · Division of Cognitive Neuroscience University of Basel

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02321852 on ClinicalTrials.gov